Bard's Third PowerPort Bellwether Is in Trial Right Now: Why an Infection Case Changes the $40 Million Story

The third bellwether trial in the Bard port catheter litigation opened on October 13, 2026, and it tests an infection claim — not a fracture. May Lattanzio alleges her PowerPort's silicone catheter caused a bloodstream infection, with trial scheduled through October 30, 2026.

After a defense verdict in the first bellwether and a $40 million plaintiff verdict in the second, this infection case will show whether juries treat infection claims the way they treated a fractured catheter case — or whether infection plaintiffs face a harder road.

Problem Solved covers complex consumer and legal stories in plain language, and this litigation is a useful example of how bellwether trials shape what happens to thousands of cases that never reach a courtroom.

  • 4,140 port lawsuits were pending in MDL 3081 as of the Judicial Panel on Multidistrict Litigation's October 1, 2026 report.
  • The second bellwether, Divelbliss, ended September 4, 2026 with a $40 million compensatory award and no punitive damages.
  • The first bellwether, Cook, ended with a defense verdict on failure-to-warn, failure-to-instruct and consumer-fraud claims in May 2026.
  • Judge David G. Campbell denied Bard's motion for summary judgment in full in the Lattanzio case on September 25, 2026.
  • Two further bellwether trials are scheduled for December 1, 2026 and February 2, 2027.

What a Bellwether Trial Is, and Why It Matters

A bellwether trial is a test case chosen from a large group of similar lawsuits to show both sides how juries respond to the evidence. A bellwether is not binding on other plaintiffs: each case still turns on its own facts. But the verdicts inform settlement talks, because they reveal which arguments persuade jurors, which injuries jurors take most seriously, and where a defendant's defenses hold up. In the Bard litigation, formally In re: Bard Implanted Port Catheter Products Liability Litigation, MDL No. 3081 in the District of Arizona, the bellwether slate was cut from six cases to five after the second scheduled case, Wanda Miller, was vacated when Ms. Miller died in early 2026 and her family chose not to continue it.

The Two Verdicts That Came Before

The first bellwether, Robert Cook, ended in a defense verdict on most claims, with the jury unable to reach a verdict on the design defect claim. The second, Kimberly Divelbliss, was a fracture case: her silicone Groshong catheter allegedly fractured, and a fragment travelled to the right atrium of her heart, where it had to be removed. She alleged heart muscle injuries and cardiac arrhythmias. On September 4, 2026, the jury found for Divelbliss on design defect and failure-to-warn claims and awarded $40 million in compensatory damages, with no punitive damages. On October 16, 2026, Bard asked for a new trial, arguing that plaintiffs' counsel improperly used information about payments to expert witnesses to influence the jury and justify the award.

Why Lattanzio Is a Different Test

Lattanzio's claim turns on infection rather than fracture. Bard argued that her claims were time-barred, that its warnings were adequate, that the design defect and misrepresentation claims failed as a matter of law, and that there was no basis for punitive damages. Judge Campbell rejected all of those arguments at the summary judgment stage, finding that each presented a question for a jury. At trial, however, infection cases raise causation questions that fracture cases often avoid. A fractured catheter with a fragment lodged in the heart is visible on imaging. An infection in a patient receiving chemotherapy, whose immune system is already compromised, invites competing explanations: the device, the treatment, the care setting, or the patient's own condition. Plaintiffs will need medical evidence tying the infection to the port and documenting its full consequences, including any port removal, hospitalisation and treatment delay.

What the Infection Verdict Could Change

If Lattanzio wins, infection plaintiffs gain leverage they did not have after Cook, and the range of cases Bard must take seriously widens beyond fracture and migration. If Bard wins, the Divelbliss verdict starts to look like a fracture-specific result rather than a signal about the whole litigation, and infection plaintiffs will face tougher settlement talks. Either way, the December and February bellwethers will add data points. No settlement has been announced in this litigation as of October 2026, and a single bellwether — win or lose — does not create one. Compensation varies widely by case, and most settlements are confidential.

Who Benefits From This — and Who Does Not

Patients whose implanted port fractured, migrated or caused a serious infection benefit most directly from following this trial, because its outcome shapes how their own claims are valued. So do patients still living with a Bard port who are weighing whether to raise a concern with their treating physician — not to remove a working device on the basis of news coverage, but to ask informed questions at their next appointment. Families of patients who died after a port complication may also benefit, since wrongful death and survival claims raise distinct proof and deadline issues that deserve early advice. This trial does not benefit everyone with a port: patients whose device worked without complication have no claim on these facts, and patients whose infection clearly traced to another source should not expect this litigation to supply an answer. Readers who want the background on the earlier verdicts can start with our October 2026 PowerPort update and our guide to blood clot and infection claims, and anyone comparing claim types should read design defect, manufacturing defect and failure to warn explained.

What to Do If You Had a Bard Port Complication

First, preserve the record: the implant record or operative report usually identifies the manufacturer and model, and imaging and explant records matter enormously in fracture cases. Second, keep a dated account of symptoms, hospital visits and any device removal, because timelines decide both causation and deadlines. Third, check the deadline in your state promptly: device cases raise complicated discovery questions about when a patient knew or should have known of the injury, and waiting can end a claim regardless of its strength. Fourth, do not stop or change cancer treatment on the basis of litigation news; discuss any device concern with the physician managing your care.

Frequently Asked Questions

Who benefits from following the Lattanzio trial?

Patients with a fractured, migrated or seriously infected Bard port benefit most, because the verdict will influence how similar claims are valued in settlement talks.

Who does not benefit, or who is not eligible?

Patients whose port worked without complication do not have a claim on these facts, and infection cases with a clear alternative cause face a much harder causation fight.

How do I start if I had a port complication?

Gather your implant record, imaging and treatment records, write down a dated symptom timeline, check your state's filing deadline, and get a case evaluation from a firm handling Bard port claims before any deadline passes.

Has Bard settled the PowerPort cases?

No settlement has been announced as of October 2026. Bellwether verdicts inform settlement talks, but they do not by themselves create a settlement program.

Does the $40 million Divelbliss verdict mean my case is worth $40 million?

That award reflected one plaintiff's fracture, heart injury and treatment history. Compensation varies widely by case, and most settlements are confidential.

When are the next PowerPort bellwether trials?

After Lattanzio, bellwether trials are scheduled for December 1, 2026 and February 2, 2027, subject to court orders.

This article is general information, not legal advice. Laws, deadlines and court schedules change; consult a qualified attorney about your own situation.

Watch on YouTube

Problem Solved on YouTube